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Abstract
Background: c-radiation is an effective treatment for cancer. There is evidence that radiotherapy supports tumor-specific
immunity. It was described that irradiation induces de novo protein synthesis and enhances antigen presentation, we
therefore investigated whether c-radiation results in increased expression of cancer-testis (CT) antigens and MHC-I, thus
allowing efficient immunological control. This is relevant because the expression of CT-antigens and MHC-I on tumor cells is
often heterogeneous. We found that the changes induced by c-radiation promote the immunological recognition of the
tumor, which is illustrated by the increased infiltration by lymphocytes after radiotherapy.
Methods/Findings: We compared the expression of CT-antigens and MHC-I in various cancer cell lines and fresh biopsies
before and after in vitro irradiation (20 Gy). Furthermore, we compared paired biopsies that were taken before and after
radiotherapy from sarcoma patients. To investigate whether the changed expression of CT-antigens and MHC-I is specific for
c-radiation or is part of a generalized stress response, we analyzed the effect of hypoxia, hyperthermia and genotoxic stress
on the expression of CT-antigens and MHC-I. In vitro irradiation of cancer cell lines and of fresh tumor biopsies induced a
higher or de novo expression of different CT-antigens and a higher expression of MHC-I in a time- and dose-dependent
fashion. Importantly, we show that irradiation of cancer cells enhances their recognition by tumor-specific CD8+ T cells. The
analysis of paired biopsies taken from a cohort of sarcoma patients before and after radiotherapy confirmed our findings
and, in addition showed that irradiation resulted in higher infiltration by lymphocytes. Other forms of stress did not have an
impact on the expression of CT-antigens or MHC-I.
Conclusions: Our findings suggest that c-radiation promotes the immunological recognition of the tumor. We therefore
propose that combining radiotherapy with treatments that support tumor specific immunity may result in increased
therapeutic efficacy.
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Introduction
c-radiation or radiotherapy is one of the most widely used
treatments for cancer [1]. Irradiation induces death of tumor cells
[2,3], but there is accumulating evidence that adaptive immunity
significantly contributes to the efficacy of radiotherapy [4]. For
example, irradiated tumors in patients and in mice are more often
infiltrated by leukocytes than the unirradiated tumors [5,6,7] and
very recent studies in preclinical models showed that the efficacy of
radiotherapy depends on the presence of CD8+ T cells [8]. The
fact that tumors are targeted and controlled by CD8+ T cells is
suggested by the increased tumor incidence in immunosuppressed
patients [9,10,11] and by the fact that tumor-specific immunity
can be detected in cancer patients [12,13,14,15]. As the
recognition of tumor cells by CD8+ T cells depends on the
presentation of tumor-associated antigens (TAAs) in the context of
MHC-I molecules, the often-heterogeneous expression of TAA
and/or MHC-I within a tumor negatively impacts on the efficacy
of tumor-specific immunity. In the present study we asked the
specific question whether irradiation induces or up-regulates the
expression of a prominent group of TAAs, the so-called CT-
antigens. The CT-antigens form an extended family of antigens
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that are expressed in a large variety of malignancies but are absent
from healthy tissue except for the testis and placenta [16,17].
Cancer patients often develop spontaneous immune responses
towards CT-antigens, which illustrates their immunogenicity [18].
Due to their immunogenicity and restricted pattern of expression,
CT-antigens are considered promising targets for immunotherapy
in cancer patients [19,20]. We observed that irradiation induced a
higher or a de novo expression of different CT-antigens as well as an
up-regulation of MHC-I expression in multiple cancer cell lines
and in fresh, ex vivo irradiated tumor biopsies. Importantly,
comparison of paired tumor sections obtained from sarcoma
patients before and after irradiation showed up-regulated or de novo
expression of MHC-I and CT-antigens and the concomitant
increase of infiltrating CD8+ T cells, suggesting that irradiation
mobilizes local, tumor-specific immune responses. Furthermore,
our findings indicate that a combination of radiotherapy and
active immunization with relevant CT-antigens may be a
treatment modality with higher efficacy compared to either
therapy alone.
Materials and Methods
Ethics Statement
The ethics committee "Ethical committee of the canton of
Zurich" specifically approved this study (Study No: EK-1017).
Cells
Cell lines. MDA-MB-469, MDA-MB-231 and MCF 7
(breast cancer cell lines), MCF 10A (normal breast cell line,
immortalized, non-transformed), Saos, LM5, 143B, HOS,
HU09, and M132 (osteosarcoma cell lines), A549, H460,
Calu1 and Calu3 (lung cancer cell lines), SK-MEL-37
(melanoma cell line) and PC3 and DU145 (prostate cancer cell
lines) were obtained from American Type Culture Collection
(Manassas, VA). The osteosarcoma cell lines were a gift from Dr.
Bruno Fuchs (Department of Orthopedics, University Clinic
Balgrist, Zurich). All cell lines and biopsies were cultured in
RPMI 1640 medium (Invitrogen, Carlsbad, CA) containing 10%
fetal bovine serum (FBS; Sigma-Aldrich Corp. St. Louis, MO),
L-glutamine and antibiotics. PC3 and DU145 were cultured in
DMEM medium (Invitrogen), containing 10% FBS, L-glutamine
and antibiotics.
Primary human cells. Human foreskin keratinocytes were
obtained as a gift from Dr. Onur Boyman (Department of
Dermatology, University Hospital Zurich) and were cultured in
Keratinocyte serum free medium (K-SFM; Invitrogen),
supplements (EGF Human Recombinant and Bovine Pituitary
Extract; Invitrogen), L-glutamine and antibiotics as described [21].
Normal human dermal fibroblasts (NHDF) were obtained from
PromoCell GmbH (Heidelberg, Germany). Human microvascular
endothelial cells (HMEC-1) were obtained as a gift from Dr.
Therese Resink (Department of Biomedicine, University Hospital
Basel) and were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen) supplemented with 5% FBS (Sigma-Aldrich)
and antibiotics. Human lung fibroblasts (MRC-5) were obtained as
a gift from Dr. Giancarlo Marra (IMCR, Zurich) and were
originally obtained from Coriell Cell Repositories (Camden, NJ)
and cultured in MEM medium (Invitrogen), containing 15% FBS,
L-glutamine and antibiotics. ZT-821 cells (primary renal cells)
were established in our lab from a single cell suspension of healthy
kidney tissue. The NHDF and ZT-821 cells were cultured in
RPMI 1640 medium (Invitrogen) containing 10% FBS (Sigma-
Aldrich), L-glutamine and antibiotics.
Treatment of cells
Ionizing radiation. Cells and fresh tumour biopsies were
exposed to c-radiation from a 60Co source. The doses of
irradiation used are described in each experiment.
Hyperthermia. Cells were incubated at 42uC for 1 h or 5 h
and cultured subsequently for 72 h at 37uC. The treated and non-
treated cells were then processed for analysis by RT-qPCR.
Hypoxia. Cells were incubated under hypoxic conditions (1%
O2 vol/vol) in a hypoxic workstation (InVivoO2-400, Ruskinn
Technology, Leeds, UK) for different time points (8 h, 48 h or
72 h). The treated and non-treated cells were then processed for
analysis by RT-qPCR.
Genotoxic stress. Cells were treated at 37uC with 1 mg/mL
cisplatin (Sigma-Aldrich Corp. St. Louis, MO) for 24 h or with
15 mM etoposide (Sigma-Aldrich) for 1 h or with 150 mM
bleomycin (Sigma-Aldrich) for 1 h. This time point was
considered as T0. At the end of the treatment, the medium was
replaced with fresh culture medium without the drug. The cells
were then cultured for additional 72 h at 37uC. Control cultures
were treated under similar experimental conditions in the absence
of the drug.
Small-molecule protein kinase inhibitors. A stock
concentration of 10 mM in 100 % dimethyl sulfoxide (DMSO)
of specific inhibitors for ataxia telangiectasia mutated (ATM), KU
55933 (Tocris bioscience, Ellisville, MO) and DNA-dependent
protein kinase catalytic subunit (DNA-PKcs), NU7441 (Tocris
bioscience) were diluted to a working concentration of 10 mM in
1% DMSO. The inhibitors were added 1 h before irradiation, and
were left in the culture throughout the experiment. Control
cultures were treated under similar experimental conditions in the
absence of the drug with 1% DMSO.
Tumor biopsies
Biopsies were obtained from the University Hospital Zurich. All
patients underwent surgery as part of their standard treatment and
signed the informed consent. The ethics committee "Ethical
committee of the canton of Zurich" specifically approved this
study (Study No: EK-1017). Immediately upon resection, biopsies
were cut into multiple pieces of 2-4 mm3. The pieces were
randomized in two batches and put into culture medium. One
batch was irradiated with a single dose of 20 Gy, whereas the other
batch served as control. The tumor pieces were cultured for 72 h
following ex vivo radiation and the gene expression was determined
by RT-qPCR analysis. Paired biopsies from sarcoma before and
after irradiation were collected for another purpose and therefore
the time points of collection after radiotherapy varied between 2-6
weeks. The tumors were irradiated in vivo with a linear accelerator
and received a dose of 50-64 Gy.
RNA extraction and preparation of cDNA
Total RNA was extracted using the RNeasy Mini Kit (Qiagen,
Valencia, CA) and was subsequently digested with DNAse I
(Invitrogen). The concentration and purity was evaluated using the
NanoDrop ND-1000 spectrophotometer (NanoDrop Technolo-
gies, Wilmington, DE). 150 ng of RNA was reverse transcribed
using the high-capacity cDNA Reverse Transcription Kit (Applied
Biosciences, Foster City, CA). The cDNA was either used
immediately for RT-qPCR reactions or stored at -20uC until
use. All kits were used according to the manufacturer’s
instructions.
RT-qPCR
The expression of CT-antigens and MHC-I was analyzed using
TaqMan gene analysis primers and TaqMan 1x universal master
RT Promotes Immune Recognition of Cancer Cells
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mix (Applied Biosystems) on a RotoGene cycler (Corbett
Research, Sydney, NSW). The reaction mixture (10 mL) consisted
of 1 mL cDNA, 3.5 mL water, 0.5 mL primer and 5 mL TaqMan
1x universal master mix. The following cycle conditions were used:
2 min 50uC, 10 min 95uC, 45 cycles of 15 s at 95uC, 1 min 60uC.
The change in expression levels of CT-antigens and MHC-I is
given as the fold increase in expression by comparing the delta-Ct
values of the treated to that of the non-treated samples after
normalization to 18S rRNA. Ct values . 38 cycles were
interpreted such that the gene is not expressed and a fold
expression , 2 was considered as no change. Each of the breast
cancer and osteosarcoma cell lines were tested in two independent
experiments and the lung carcinoma and the prostate carcinoma
cell lines in one. Each sample was loaded in duplicates/triplicates
for each of the RT-qPCR experiments.
Flow cytometry
Cells were stained with PE-labeled anti-HLA-A,B,C (clone
G46-2.6, 1:100), FITC-labeled anti-b2-microglobulin (clone
TU99, 1:100) (BD Pharmingen, San Diego, CA) and propidium
iodide (PI; Sigma). Samples were measured with a FACS Calibur
(BD) and analyzed with FlowJo software (Treestar) after gating on
live (PI-negative) cells. Appropriate isotype controls were used.
Immunohistochemistry
Formalin-fixed, paraffin-embedded paired tissue sections ob-
tained from sarcoma patients before and after irradiation were
stained with mouse anti-human monoclonal antibodies against
CD4 (clone 1F6, 1:30, ZYMED Laboratories Inc.), CD8 (clone
C8/114B, 1:100, DAKO A/S, Carpinteria, CA), granzyme B
(clone Gr B-7, 1:25, DAKO A/S), MHC-I (clone C21, 1:1000,
RDI Research Diagnostics, Inc.), CT7 (clone CT7-33, 1:80,
DAKO A/S), CT10 (rabbit polyclonal, 1:500, ProteinTech
Group, Inc.), NY-ESO-1 (clone E978, 1:50, ZYMED) and
Perforin (clone 5B10, 1:20, Novocastra Laboratories Ltd). Sections
were counterstained with hematoxylin, dehydrated and mounted.
All sections were stained either with the Ventana Benchmark
automated staining system (Ventana Medical Systems, Tucson,
AZ) using Ventana reagents for the entire procedure for NY-ESO-
1, CT7, granzyme B, CD4, CD8 and perforin and BondMax
(Vison BioSystems, Newcastle upon Tyne, UK) for CT10 and
MHC-I. UView (Ventana) or Refine DAB (Vision BioSystems)
were used as chromogens against the primary antibodies. Images
of the stained sections were acquired on Zeiss-Axiovert 200 M
(Carl Zeiss Light Microscopy Go¨ttingen, Gearmany) inverse
microscope using Carl Zeiss Axiovision CD28 imaging system.
The stainings were scored on a scale of 0 to 5 for the expression of
NY-ESO-1, MAGE-C1/CT7, and MAGE-C2/CT10 as a
percentage, based on the number of positive cells expressing the
antigen to the total number of cells in a high power field (HPF)
using a 40X objective lens. The scoring for MHC-I expression was
done based on the intensity of staining. The tumor infiltrates were
calculated as the number of cells expressing CD4, CD8 and
granzyme per HPF using a 40X objective. Each stained section
was evaluated in five different regions (for detailed list of scores see
Table S4). Three individuals performed the scoring blindly and
independently for the MHC-I stainings and two individuals
performed the scoring blindly for the other stainings.
Immunofluorescence
Cells (10’000-20’000 cells in 1 mL medium) were plated on
compartmented culture slides (BD Biosciences) to adhere over-
night. Cells were then fixed with 4% paraformaldehyde for 15 min
at room temperature, permeabilized with 0.1% TritonX-100
(Sigma-Aldrich) for 5 min at room temperature, followed by
blocking with 10% BSA/PBS for 30 min at room temperature.
The cells were then incubated with monoclonal mouse antibodies
against NY-ESO-1 (clone E978, 1:500, Invitrogen) or MAGE-C1/
CT7 (clone CT7-33, 1: 500, Dako) in 10% BSA/PBS for 1 h at
room temperature in the dark, followed by incubation with FITC-
labeled secondary antibody goat anti-mouse IgG1 (Poly4053,
1:2000, Biolegend) for 15 min at room temperature in the dark.
The slides were counterstained with 4’,6’-diamidino-2-phenylin-
dole hydrochloride (DAPI, 1:500) for 2 minutes in the dark and
inspected using a Zeiss-Axiovert 200 M inverse microscope and a
Carl Zeiss Axiovision CD28 imaging system.
Western blot analysis
Irradiated and non-irradiated cells were checked for the protein
expression using monoclonal mouse antibodies against NY-ESO-1
(clone E978, 1:500, Invitrogen) or MAGE-C1/CT7 (clone CT7-
33, 1: 500, Dako) and b-actin (clone 4i374, 1:8000, Santa Cruz
Biotech, CA). The effect of genotoxic agents and DNA-PKcs and
ATM inhibition, on the c-irradiation induced gene expression in
cells was evaluated by using antibodies against pS2056-DNA-PKcs
(rabbit polyclonal to phospho S2056-DNA-PKcs, 1:300, Abcam
Inc, MA), FANC-D2 (clone Fl17, 1:200, Santa Cruz Biotech,
CA), pS1981-ATM (clone EP1890Y, 1:5000, Eitomics, CA) and
pS15-p53 (clone 16G8, 1:1000, Cell Signaling Technology, MA).
Followed by incubation with the secondary antibody, polyclonal
goat anti-mouse IgG1 HRP (Poly4053, 1:10000, Biolegend) or
polyclonal goat anti-rabbit HRP (1:10000, Abcam). ECL reagent
(Amersham, UK) was used as luminescence substrate.
CD107a Degranulation Assay
Recognition of cells expressing NY-ESO-1 following irradiation
by antigen-specific CD8+ T cells was tested using the CD107a
degranulation assay. Three x 105 NY-ESO-1157-165/HLA-A2-
specific cloned CD8+ T cells (generated as described [22]) were
incubated with 106 CFSE-labeled (1 mM) HLA-A2+ MDA-MB-
469 cells – that were or were not irradiated with 20 Gy 72 h earlier
– in a 96-well microtiter roundbottom plate in a final volume of
200 mL RPMI + 10% FCS and antibiotics in the presence of PE-
labeled anti-CD107a (1:20, BioLegend, SD, California). As
positive control, MDA-MB-469 cells were loaded with 10-6 M
NY-ESO-1157-165 peptide. Two independent T cell clones (2A7
and 2B5) were used and all cultures were performed in duplicate.
The incubation was performed at 37uC for 4 h. The cells were
collected and washed in 2 mL FACS-buffer (FB) followed by
staining with pacific blue-labeled anti-CD8 (BioLegend) in 50 mL
FB for 30 min at 4uC. The cells were washed once with 2 mL FB
and resuspended in 200 mL FB. Samples were measured on CyAn
ADP9 (Beckman Coulter Inc, Fl, USA) and analyzed with FlowJo
software (Treestar).
Results
In vitro c-radiation up-regulates transcripts of CT-
antigens and MHC-I molecules
Breast, osteosarcoma, lung and prostate cancer and normal
primary cells were exposed to a single-dose radiation of 20 Gy,
after 72 h the cells were harvested and analyzed for the expression
of CT-antigens and MHC-I by RT-qPCR. Most of these cancer
cell lines expressed undetectable or very low levels of CT-antigens
under standard culture conditions. In contrast, c-radiated cells
showed de novo or up-regulated expression of various CT-antigens
in a randomized fashion (Figure 1A-D). In a panel of the four
cancer cell line types, c-radiation was found to have the most
RT Promotes Immune Recognition of Cancer Cells
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profound effect on the breast cancer and osteosarcoma cell lines
and the least on the prostate cancer cell lines. The up-regulation of
MHC-I and CT-antigens upon c-radiation seems to be a specific
feature of malignant cells, as this was not observed in any of the
normal primary cells that we tested here (ZT-812, human foreskin
keratinocytes, HMEC-1, MRC-5, NHDF and MCF 10A, Figure
S1A, S1B). The melanoma cell line SK-MEL-37 is known to
express all tested CT-antigens under normal culture conditions
and was therefore included as the positive control. Irradiation of
this cell line resulted in a clear up-regulation of all the CT-antigens
and MHC-I (data not shown). We detected an increased
expression of CT-antigens and MHC-I as early as 24 h after
irradiation in some cases and a steady increase in gene expression
was observed up to 96 h after irradiation. As we observed
substantial cell death at 96 h after irradiation, we performed all
further analyses at 72 h after irradiation. As radiotherapy can be
given as a single high dose (20 Gy) or as fractionated doses, we
irradiated selected cell lines (the breast cancer cell lines MDA-MB-
469 and MCF7, as well as the osteosarcoma cell lines Saos, HOS,
LM5 and 143B, with 2 Gy per day on 10 consecutive days. This
protocol resulted in similar change of CT-antigen and MHC-I
expression as observed with a single dose of 20 Gy (Figure S2A,
S2B). A single dose of 20 Gy was used in all further experiments.
In vitro c-radiation up-regulates CT-antigens and MHC-I
molecules at the protein level
To confirm the irradiation-induced expression of CT-antigens
on the protein level, we stained irradiated and non-irradiated
MDA-MB-469 cells with antibodies against NY-ESO-1 and CT7
and analyzed the expression of CT7 and NY-ESO-1 at different
time points after irradiation by immunofluorescence microscopy
and by Western blotting. The melanoma cell line SK-MEL-37
constitutively expresses NY-ESO-1 and CT7 and was used as
positive control. We observed the de novo expression of both the
Figure 1. c-radiation up-regulates CT-antigens and MHC-I molecules on the mRNA level. Established cancer cell lines were exposed to
single dose irradiation of 20 Gy and the mRNA expression of CT-antigens and MHC-I was determined 72 h later by RT-qPCR. (A) breast cancer cell
lines, (B) osteosarcoma cell lines, (C) lung cancer cell lines, (D) prostate cancer cell lines. All Ct values are normalized to 18S rRNA and the data are
presented as the fold increase of expression in irradiated compared to the corresponding untreated samples. Because fold expression can’t be
calculated for genes that are de novo expressed upon irradiation, we put the symbols in such cases above the thin horizontal line in (A).
doi:10.1371/journal.pone.0028217.g001
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Figure 2. c-radiation up-regulates CT-antigens and MHC-I molecules on the protein level. (A) Immunofluorescence of MDA-MB-469 and
SK-MEL-37 cells exposed to a single dose irradiation of 20 Gy and stained with antibodies against NY-ESO-1 and CT7 at different time points after
irradiation. (B) MDA-MB-469, SK-MEL-37 and MCF 10A cell lines were exposed to a single dose of 20 Gy and the expression of NY-ESO-1 and CT7 was
analyzed by Western blotting 72 h later. (C) breast cancer and (D) osteosarcoma cell lines were exposed to single dose irradiation of 20 Gy and the
expression of HLA-ABC and b2microglobulin was quantified at different time points after irradiation by flow cytometry. RAD: indicates c-radiation.
doi:10.1371/journal.pone.0028217.g002
RT Promotes Immune Recognition of Cancer Cells
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CT-antigens upon irradiation that increased with time
(Figure 2A, 2B), thus confirming the data obtained by RT-
qPCR. Irradiation of the normal breast cell line MCF10A did not
result in increased NY-ESO-1 or CT7 protein levels (Figure 2B).
To study the effect of c-radiation on the surface expression of
MHC-I at the protein level, we irradiated multiple cancer cell lines
(breast carcinoma and osteosarcoma) and normal primary cells of
different origins, followed by flowcytometric detection of surface
MHC-I, and observed that irradiation resulted in a time-
dependent increase of MHC-I surface expression on different
cancer cell lines (Figure 2C, 2D) but not in the normal primary
cells (Figure S1B).
Irradiation of cancer cells enhances T cell recognition in
vitro
In order to determine whether irradiation-induced up-regula-
tion of CT-antigens and MHC-I results in increased recognition
by antigen-specific CD8+ T cells, we measured degranulation [23–
24] of NY-ESO-1157-165/HLA-A2-specific cloned CD8
+ T cells
upon incubation with irradiated and non-irradiated HLA-A2+
MDA-MB-469 breast cancer cells. MDA-MB-469 cells are
negative for NY-ESO-1, but become positive upon irradiation
(Figure 1A, 2A, 2B). We found that only irradiated MDA-MB-
469 cells induced degranulation of two independent NY-ESO-
1157-165-specific CD8
+ T cell clones (2A7, 2B5) (Figure 3).
Irradiation did not further increase the degranulation when
peptide-loaded MDA-MB-469 cells were used (data not shown),
indicating that not the amount of MHC-I but the amount of NY-
ESO-1157-165 presented by MHC-I was the limiting factor in
unirradiated MDA-MB-469 cells, which fits the fact that
irradiation induced de novo expression of NY-ESO-1 in MDA-
MB-469 cells (Figure 1A, 2).
Ex vivo irradiation of fresh tumor biopsies induces up-
regulation of CT-antigens and MHC-I
To expand our findings to clinically relevant material, we
collected fresh tumor biopsies from 23 different cancer patients,
cut those into at least 50 small pieces, and randomized them into
two experimental groups. We irradiated one group of biopsies with
20 Gy, whereas the others served as control, and analyzed the
expression of CT-antigens and MHC-I 72 h later by RT-qPCR
and immunohistochemistry. These results confirmed the findings
we obtained with cancer cell lines, that c-radiation often induced
increased expression of CT-antigens and/or MHC-I (Figure 4A,
4B, Table S1). Importantly, our results suggest that heteroge-
neous expression of CT-antigens and/or MHC-I can become
more homogeneous upon radiotherapy, which obviously supports
immunological control of the tumor.
In vivo irradiation of human sarcoma results in increased
expression of CT-antigens and MHC-I and in lymphocyte
infiltration
Finally, we compared the expression of CT-antigens, MHC-I
and the infiltration by lymphocytes in 15 paired paraffin-sections
obtained from sarcoma patients before and after radiotherapy by
immunohistochemistry. We found that radiotherapy resulted in
Figure 3. Irradiation induced enhances T cell recognition of cancer cells.106 CFSE-labeled HLA-A2+ MDA-MB-469 breast cancer cells were
irradiated or not with a single dose of 20 Gy and were incubated 72 h later with 36105 NY-ESO-1157-165/HLA-A2-specific CD8+ T cell clones (clone 2A7
and clone 2B5) in the presence PE-labeled anti-CD107a-PE for 4 h at 37uC. The cells were then stained with pacific blue-labeled anti-CD8- for 30 min
at 4uC. Peptide-loaded MDA-MB-469 cells were used as positive control. All cultures were performed in duplicate. The degranulation was measured as
percentage CD107a+ cells of CD8+ cells after gating on CFSE-negative cells by flow cytometry.
doi:10.1371/journal.pone.0028217.g003
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substantial up-regulation or de novo expression of CT-antigens
and/or MHC-I molecules, which was accompanied by an
increased infiltration by lymphocytes and granzyme expression
in 7/15 and 12/15 samples, respectively (Figure 5A-D, Table
S2, S3).
Other forms of stress have no impact on the expression
of CT-antigens or MHC-I in vitro
Stress and environmental alterations induce changes in the
transcriptional profile in order to cope with those assaults
[25,26,27]. As irradiation induces DNA-damage, we investigated
whether the up-regulated expression of MHC-I and CT-antigens
would also occur after exposure of cell lines to other treatments
that induce DNA damage such as cisplatin, etoposide and the
radiomimetic drug bleomycin. MDA-MB-469 and SK-MEL-37
cells were treated separately with each of the DNA-damaging
agents and RNA levels were monitored at different time points
following treatment. Our results show that none of these agents
up-regulated the expression of CT-antigens and MHC-I (Figure
S3B-D). However, the hallmark genes pS15-p53 and FANC-D2
were up-regulated following treatment, indicating that these agents
induced stress at the concentration used (Figure S3A). Further-
more, we tested whether other types of cancer-related stress,
including elevated temperatures or low oxygen levels, induced
increased expression of CT-antigens and/or MHC-I. We found
that none of these treatments impacted on the expression of CT-
antigens and MHC-I whereas the signature gene CA9 was up-
regulated (Figure S4A, S4B). Together, these results suggest that
the increased expression of CT-antigens and MHC-I by cancer
cell lines is a specific response to c-radiation and does not occur
after exposition to other inducers of various stress response
pathways.
The ATM and DNA-PK signaling pathways are
dispensable for c-radiation-induced expression of CT-
antigens and MHC-I
The activation of DNA-damage repair checkpoint pathways as
a response to genotoxic insult helps to maintain the genomic
integrity in mammalian cells [28]. DNA damage triggers the
activation of various serine/threonine protein kinases, which
constitute the primary transducers in the signaling cascade and of
which, ataxia telangiectasia mutated (ATM) and DNA-dependent
Figure 4. Ex vivo irradiation up-regulates CT-antigens and MHC-I in fresh tumor biopsies. Fresh tumor explants from different cancer
patients (n = 23) were irradiated or not with single-dose of 20 Gy. The diagnosis of the individual patients is shown in supplementary Table S1. (A)
After 72 h, the irradiated and control explants were analyzed for the expression of NY-ESO-1 and MHC-I by RT-qPCR. (B) Representative sections
(patient number 9 and 20) depicting the expression of NY-ESO-1 and MHC-I by immunohistochemistry (20X magnification). NR indicates non-radiated
and RAD indicates corresponding irradiated sections.
doi:10.1371/journal.pone.0028217.g004
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protein kinases (DNA-PKcs) are of utmost importance [29]. The
ATM protein kinase is a critical intermediate in a number of
cellular responses to c-radiation and other forms of stress [30]. We
thus investigated whether the up-regulation of CT-antigen and
MHC-I expression in response to c-radiation depends on the
activation of ATM and/or DNA-PKcs. We irradiated MDA-MB-
469 and SK-MEL-37 cells with a single dose of c-radiation (20 Gy)
in the presence or absence of specific inhibitors of ATM
(KU55933) and DNA-PK (NU7441). 10 mM of the inhibitor was
added 1 h before irradiation, and was left in the culture
throughout the experiment. We observed that ATM and DNA-
PK as well as p53 were phosphorylated in response to c-radiation,
Figure 5. Radiotherapy induced expression of CT-antigens and MHC-I and lymphocyte infiltration in sarcoma patients. Paraffin-
embedded paired tissue sections obtained from sarcoma patients (n = 15) before and after irradiation were analyzed by immunohistochemistry for
(A) presence of CD8+, CD4+ and granzyme+ cells, (B) expression of CT7, NY-ESO-1 and CT10 and (C) MHC-I expression. The CT-antigens were scored as
the mean percentage of live cells expressing the antigen to the total number of cells in five high power fields (40X objective). The infiltration by
lymphocytes was taken as the mean by counting the number of cells expressing CD4, CD8 and granzyme in five high power fields, and MHC-I was
scored based on the intensity of the staining. (D) Representative sections showing the expression of CT-antigens and MHC-I and infiltration of
lymphocytes before and after radiotherapy by immunohistochemistry. Depicted are: patient F for the expression of CT7, patient A for CT10, patient K
for NY-ESO-1, patient D for CD4 and MHC-I and patient E for CD8 expression. NR indicates non-radiated and RAD indicates corresponding irradiated
sections. Pt: indicates patient number. Patient information is listed in supplementary Table S2.
doi:10.1371/journal.pone.0028217.g005
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which was prevented by the specific inhibitors (Figure 6A, 6B).
However, neither ATM- nor DNA-PK inhibition prevented the
up-regulation of CT-antigen and MHC-I expression (Figure 6A,
6B, S5A, S5B). These results indicate that the ATM and DNA-
PK DNA-damage signaling pathways are not crucially involved in
the up-regulation of CT-antigen and MHC-I expression upon c-
radiation.
Discussion
Radiotherapy is one of the most widely used and successful
cancer treatments to date [31]. Recent studies described that c-
radiation leads to a plethora of alterations in the tumor cells [32],
including the de novo synthesis of particular proteins and the up-
regulation of MHC-I expression [1,32,33]. In addition, irradiated
tumors are often more infiltrated by leukocytes than the non-
irradiated tumors and studies using preclinical models showed that
the therapeutic success of high-dose irradiation depends on
adaptive immunity [34]. We therefore hypothesized that the
expression of a specific class of TAAs, the so-called CT-antigens, is
induced by irradiation, thus making tumors more susceptible to
recognition by effector T cells. In addition the de novo expression of
highly immunogenic CT-antigens may result in tumor-specific
immune responses that are not yet compromised by mechanisms
of central [35] or peripheral tolerance. Because cancer cells can
only be recognized by CD8+ T cells when they express MHC-I
and because tumors often express very low levels of MHC-I or are
even negative, radiation-induced up-regulation of MHC-I may
further support immune recognition. We observed that irradiation
induced de novo or up-regulated expression of various CT-antigens
and MHC-I in a randomized fashion and independent of the tissue
origin of the malignancy. We confirmed this effect using
established cancer cell lines, fresh ex vivo irradiated tumors and
paired biopsies from sarcoma patients before and after radiother-
apy. Studies have shown that the radiation-induced up-regulation
of MHC-I makes the tumor cells more susceptible to lysis by CTL
in vitro [1,36]. We confirm these data here and show that
irradiation of tumor cells not only up-regulates the expression of
CT-antigens and MHC-I but also increases their recognition by
CD8+ T cells. The up-regulated expression of CT-antigens and
MHC-I seems specific for c-radiation, as similar changes in gene
expression were not observed upon other treatments that induce
DNA-damage, upon hypoxia or hyperthermia. We could not
identify the molecular mechanism underlying radiation-induced
Figure 6. The ATM and DNA-PK signaling pathways are dispensable for c-radiation induced expression of CT-antigens and MHC-I.
SK-MEL-37 and MDA-MB-469 cells were irradiated or not in the presence or absence of inhibitors specific for ATM (ATMi) and DNA-PKcs (DNAPKi) and
whole cell extract was analyzed by Western blotting. (A) Detection of phosphorylated ATM, p53, CT7 and NY-ESO-1 and (B) phosphorylated DNA-PK,
CT7 and NY-ESO-1. Anti-b-actin specific antibodies served as loading controls.
doi:10.1371/journal.pone.0028217.g006
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up-regulation of CT-antigens and MHC-I expression, but we
excluded the involvement of the ATM or DNA-PK signaling
pathways. Previous studies have shown that the expression of CT-
antigens is regulated through demethylation of their promoter
CpGs [37]. In addition, all CT-antigen genes that are expressed in
tumors or testis can be induced in vitro by DNA demethylation
[38]. However, when we compared the methylation status of
CpGs in the promoter region of NY-ESO-1 of irradiated and non-
irradiated MDA-MB-469 and MCF 7 cells, we found no difference
(data not shown). This result suggests that the up-regulated
expression of CT- antigens and MHC-I upon c-radiation is
regulated through another pathway than demethylation of CpG
islands in the promoter region. However, as we performed this
experiment only with a limited number of cell lines and we
analyzed only one CpG region in the promoter of NY-ESO-1, we
can’t fully exclude that other CpG regions may have been
hypomethylated following irradiation.
Our data strongly suggests that irradiation supports immu-
nological control of tumors through the expression of novel
tumor-associated antigens to which the immune response
presumably is not compromised. In addition, the concomitant
up-regulation of MHC-I expression makes irradiated tumor cells
more susceptible to tumor-specific CTL. It is currently not
known whether the increased infiltration by CD8+ T cells
upon irradiation is a direct effect of increased local expres-
sion of cognate peptide/MHC-I complexes or whether other
factors such as local inflammation or changes in vasculature
contribute.
It may be interesting to combine radiotherapy with immuniza-
tion to maximally exploit the changes induced by irradiation.
However, the fact that it seems unpredictable as to which CT-
antigens will show de novo or up-regulated expression makes it
difficult to choose the correct antigen for immunization, at least in
those cases where tumor biopsies are not available. Nevertheless,
the combination of radiotherapy with treatments that generally
stimulate the immune system such as the blockade of co-inhibitory
interactions (CTLA-4, PD-1) or mediators (IL-10, TGF-b, IDO)
or activation of dendritic cells by innate stimuli may further
improve the efficacy of radiotherapy.
Supporting Information
Figure S1 c-radiation does not effect the expression of
CT-antigens and MHC-I molecules in vitro. Normal
primary cell cultures – HMEC-1, human foreskin keratinocytes,
MCF-10A, MRC-5, NHDF and ZT-812, were exposed to a single
dose irradiation of 20 Gy and the CT-antigen and MHC-I
expression was determined at the (A) mRNA level by RT-qPCR,
and (B) protein level by flow cytometry.
(TIF)
Figure S2 Fractionated c-radiation results in a time-
dependent up-regulation of CT-antigens and MHC-I
molecules in vitro. Established cancer cell lines were exposed
to fractionated irradiation of 2 Gy on 10 consecutive days to
obtain a cumulative dose of 20 Gy. (A) breast cancer cell lines, (B)
osteosarcoma cell lines. All Ct values are normalized to 18S rRNA
and the data are presented as the fold increase of expression in
irradiated (at 24 h, 48 h and 72 h from the last dose of irradiation)
compared to the corresponding untreated samples.
(TIF)
Figure S3 Genotoxic stress has no impact on the
expression of CT-antigens or MHC-I in vitro. The breast
cancer cell line MDA-MB-469 and the melanoma cell line SK-
MEL-37 and the normal breast cell line MCF 10A were exposed
to other forms of stress and gene expression was analyzed after
72 h treatment with DNA-damaging agents. (A) Treatment with
DNA-damaging agents followed by immunoblotting to detect the
activation of hallmark genes p53 and FANC-D2. The same
samples were also subjected to RT-qPCR analysis for the
expression of CT-antigens and MHC-I at different time points
following treatment with (B) bleomycin, (C) cisplatin and (D)
etoposide. All Ct values are normalized to 18S rRNA and the data
are presented as the fold increase of expression in treated
compared to the corresponding untreated samples.
(TIF)
Figure S4 Other forms of stress have no impact on the
expression of CT-antigens or MHC-I in vitro. MDA-MB-
469 and SK-MEL-37 cells were exposed to (A) hyperthermia and
(B) hypoxia and the gene expression following treatment was
monitored at different time points by RT-qPCR analysis. All Ct
values are normalized to 18S rRNA and the data are presented as
the fold increase of expression in treated compared to the
corresponding untreated samples.
(TIF)
Figure S5 c-radiation induced expression of CT-anti-
gens and MHC-I is not dependent on the activation of
ATM, DNA-PK signaling pathways. The breast cancer cell
line MDA-MB-469, the melanoma cell line SK-MEL-37 and the
normal cell line MCF 10A were exposed or not to a single dose c-
radiation of 20 Gy in the presence or absence of specific inhibitors
of the DNA-damage repair pathways (A) ATM or (B) DNA-PKcs,
followed by RT-qPCR analysis for gene expression 72 h following
irradiation. All Ct values are normalized to 18S rRNA and the
data are presented as the fold increase of expression in treated
compared to the corresponding untreated samples.
(TIF)
Table S1 CT-antigens and MHC-I expression in fresh
tumor biopsies following ex vivo radiation. Fold increase
in expression of CT-antigens and MHC-I in fresh tumor biopsies
following 20 Gy ex vivo c-radiation. All characters in bold represent
up-regulation following ex vivo c-radiation. ND: indicates non-
detected. All Ct values are normalized to 18S rRNA and the data
are presented as the fold increase of expression in treated
compared to the corresponding untreated samples.
(DOC)
Table S2 Increased expression of CT-antigens and
lymphocyte infiltration in sarcoma patients after radio-
therapy. (A) Information of sarcoma patients treated with
radiotherapy with immunohistochemical scores for T cell
infiltration and expression of CT-antigens. All characters in bold
represent up-regulation following radiotherapy. MPNST: malig-
nant peripheral nerve sheath tumour, NOS: not otherwise
specified. NR indicates non-radiated and RAD indicates corre-
sponding irradiated sections.
(DOC)
Table S3 Radiotherapy up-regulates the expression of
MHC-I in sarcoma patients. MHC-I expression in sarcoma
patients following radiotherapy. All characters in bold represent
up-regulation following radiotherapy. NR indicates non-radiated
and RAD indicates corresponding irradiated sections.
(DOC)
Table S4 Quantification of CT-antigen and MHC-I
expression in sarcoma patients.
(DOC)
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